CONTACT YOUR POLICYMAKERS
Email your governor and state Medicaid director today urging them to commit to lifting these barriers for Medicaid beneficiaries to eliminate hepatitis C.
Hepatitis C is our nation’s deadliest bloodborne infectious disease, yet many state Medicaid programs have discriminatory restrictions that keep Americans from being cured and stop us from ending the epidemic.
As of February 2023, the following 21 states have removed prior authorization for most patients: Alaska, Arizona, California, Colorado, DC, Hawaii, Idaho, Indiana, Louisiana, Massachusetts, Michigan, Missouri, New Hampshire, New York, Oklahoma, Oregon, Rhode Island, Texas, Virginia, Washington, Wisconsin.
The above grades reflect our most up-to-date assessment of Medicaid recipients’ ability to access HCV treatment in jurisdictions across the country. For a more detailed breakdown of our assessment criteria, check out our comprehensive rubric or complete state-by-state assessments.
Citation: Center for Health Law and Policy Innovation & National Viral Hepatitis Roundtable, Hepatitis C: State of Medicaid Access (2023), www.stateofhepc.org
FOR IMMEDIATE RELEASE South Dakota Medicaid removes fibrosis and sobriety requirements for hepatitis C treatment With this change, Arkansas is now the only state still requiring proof of liver damage… [Read More]
Newly updated for 2023, state report cards show decrease in substance use restrictions and prior authorization requirements, need for parity with managed care organizationsÂ
FOR IMMEDIATE RELEASE Colorado, Oregon, and Texas Are Lifting Barriers to HCV Treatment for Medicaid Recipients These states join a growing tide of prior authorization removals for a total of… [Read More]
Email your governor and state Medicaid director today urging them to commit to lifting these barriers for Medicaid beneficiaries to eliminate hepatitis C.
Access our infographics, social media toolkit and digital resources.
Join the NVHR Voices4Hep network to connect with advocates across the country pushing for policies that eliminate hepatitis C by 2030.
@2023 HEPATITIS C: STATE OF MEDICAID ACCESS